New cancer drug injected into tumors shows promise in early trial

NCT ID NCT07395258

Terminated Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The main goal is to find a safe dose and see if the combination can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 3923948 (injected into the tumor) and ezabenlimab (a checkpoint inhibitor given by IV)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 60 participants, so the drug may not work or could have serious side effects. The trial is currently suspended, which adds uncertainty.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.